Tactile Systems Technology, Inc. reports news as a medical technology company that develops and markets at-home therapies for chronic disorders. Its updates center on lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease, including products and platforms such as Flexitouch Plus, AffloVest airway clearance devices and LymphaTech's digital 3D measurement and monitoring technology.
Recurring company developments include quarterly financial results, clinical evidence for home-based therapies, FDA device clearances, product portfolio expansion, order-management and reimbursement workflow initiatives, acquisitions, share repurchase activity and board governance changes. The company's news also describes its work with clinicians to expand awareness and access to care for patients using at-home therapy systems.
Tactile Medical (Nasdaq: TCMD) reported Q4 2025 revenue of $103.6M (+21% YoY) and full-year 2025 revenue of $329.5M (+12% YoY). Gross margin expanded to 78% in Q4 and 76% for the year. Adjusted EBITDA rose to $22.9M in Q4 and $44.8M for 2025.
Key balance-sheet moves: repaid $26.3M term loan, repurchased $26.5M of stock, and ended 2025 with $83.4M cash. 2026 guidance: revenue $357M–$365M and adjusted EBITDA $49M–$51M.
Tactile Medical (Nasdaq: TCMD) acquired LymphaTech on February 17, 2026 for an upfront cash payment of $6.8 million, plus potential milestone-based additional consideration. The deal adds LymphaTech’s clinically validated 3D full-body measurement platform to Tactile’s lymphedema portfolio and brings founders into Tactile to drive commercialization and research.
The acquisition aims to improve disease identification, enable longitudinal monitoring, support compression garment digitization, and strengthen R&D for next‑generation lymphatic therapies.
Tactile Medical (Nasdaq: TCMD) will release fourth quarter and fiscal year 2025 financial results after the market closes on February 17, 2026. Management will host a conference call and Q&A at 5:00 p.m. ET the same day.
Dial-in details: 877-407-3088 (international 201-389-0927), access code 13758303. A live webcast and archived replay will be available at investors.tactilemedical.com and a phone replay for two weeks.
About Tactile Medical: the company develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Tactile Medical (Nasdaq: TCMD) said management will participate in the Piper Sandler 37th Annual Healthcare Conference at the Lotte New York Palace in New York, NY from December 2–4, 2025.
The company will take part in a fireside chat on December 2, 2025 at 8:00 a.m. Central Time. A live audio webcast will be available in the Events & Webcasts section of the company investor relations site (http://investors.tactilemedical.com), and an archive will be posted for replay after the conference.
Tactile Medical (Nasdaq: TCMD) reported Q3 2025 results on November 3, 2025, with total revenue $85.8M (+17% YoY), gross margin 76%, net income $8.2M ($0.36 diluted) and Adjusted EBITDA $14.4M. The company repaid its $24.0M term loan, refinanced its revolver to $40M capacity, and authorized a $25M share repurchase program (expires Nov 3, 2027). Full‑year 2025 guidance was raised to $317M–$321M revenue and $38M–$39.5M adjusted EBITDA. Cash was $66.0M at Sept 30, 2025.
Tactile Medical (Nasdaq: TCMD) presented six-month results from a large randomized controlled trial showing sustained clinical benefits of Flexitouch Plus as first-line therapy for head and neck cancer–related lymphedema.
Key findings: sustained symptom improvement in both study arms, objective swelling reductions at 13 of 19 internal sites with statistically significant decreases at the base of tongue (p=0.008) and arytenoids (p=0.023), and clinician-reported measures favoring Flexitouch Plus. The trial enrolled 236 patients across 10 centers and confirms durability of benefit through six months following earlier two-month data.
Tactile Medical (Nasdaq: TCMD) announced it will release third quarter fiscal 2025 financial results after market close on Monday, November 3, 2025. Management will host a conference call with Q&A on November 3, 2025 at 5:00 p.m. ET.
Investors can join by phone at 877-407-3088 (international 201-389-0927) using access code 13755883, or listen via live webcast at investors.tactilemedical.com. A replay will be available for two weeks at 877-660-6853 (international 201-612-7415), access code 13755883. The webcast will be archived on the investor site.
About the company: Tactile Medical develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease to expand access and improve patient quality of life.
Tactile Systems Technology (NASDAQ: TCMD) reported Q2 2025 financial results with total revenue increasing 7.8% year-over-year to $78.9 million. The company achieved a gross margin of 75% and net income of $3.2 million, compared to $4.3 million in Q2 2024.
Key highlights include a 52% increase in airway clearance product sales and a 2% increase in lymphedema product line revenue. The company completed its $30 million share repurchase program, with $16.5 million repurchased in Q2. Management updated 2025 guidance, now expecting full-year revenue of $310-315 million and adjusted EBITDA of $33-35 million.
Tactile Medical (NASDAQ: TCMD), a medical technology company specializing in at-home therapies for chronic conditions, has scheduled its Q2 2025 earnings release for August 4, 2025 after market close.
The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day. Investors can participate via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13754589, or through a live webcast on the company's investor relations website.
Tactile Medical focuses on treating conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, helping patients manage their care at home.